TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00667082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPI-0052 (marizomib) + vorinostat
Description: NPI-0052 IV injection over 1 to 10 minutes at doses ranging from 0.15 to 0.7 mg/m2 on Days 1, 8, and 15 of each 28-day Cycle~Oral vorinostat 300 mg was administered with food on Days 1 to 16 of each 28-day Cycle
Study: NCT03521063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Drug: Budesonide inhalation suspension
Study: NCT01906788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2
Study: NCT01662336

Intervention type: DRUG
Intervention: Lopinavir / ritonavir
Description: Prescribed according to the product monograph and physician's discretion.

Intervention type: BEHAVIORAL
Intervention: Kaletra Adherence Support Assistance Program
Description: A customized support network for patients treated with lopinavir / ritonavir that offers individual counseling with an HIV experienced nurse who assists patients with various aspects of their therapy including life-style changes, emotional stress, and adverse events, and may provide access to various healthcare professionals or may offer other types of support such as transportation, exercise, etc.
Study: NCT03521063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poractant Alfa
Description: Drug: Poractant alfa intratracheal suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poractant Alfa
Description: Drug: Poractant alfa intratracheal suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Sodium chloride injection 0.9%
Study: NCT00038649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: 400 mg orally twice daily
Study: NCT03277209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
Study: NCT03167593

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus coryniformis K8 CECT5711
Description: Lactobacillus coryniformis CECT5711

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control placebo
Description: Maltodextrin
Study: NCT03841890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Clarus Video System as a video stylet
Description: video-guided intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Clarus Video System as a lightwand
Description: The endotracheal tube will be initially guided into larynx in the dimly lit operating room by a bright glow moving in the anterior soft tissue of the neck and finally by the image of the trachea rings on the video screen.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: direct laryngoscope
Description: Macintosh laryngoscope size 3
Study: NCT02030483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclb will be given at predefined dose level of 75 mg, 100 mg, 125 mg, or 150 mg days 1-14 every 28 days (days 0-14 for cycle 1 only).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle (Day 1 dosing is omitted for cycle 1 only).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide at predefined dose level of 5mg, 10 mg, 15 mg, 25 mg daily for days 8-21 (or days 1-21, depending on dose level cohort).
Study: NCT00105573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal interpersonal psychotherapy (IP)
Description: Participants will receive 16 weekly sessions of maternal IP designed to directly treat maternal depression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal interpersonal psychotherapy (IP)
Description: Participants will receive 16 weekly sessions of maternal IP designed to directly treat maternal depression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant-parent psychotherapy
Description: Participants will receive 1 year of in-home, infant-parent psychotherapy, an intervention addressing relationship difficulties between depressed mothers and their infants.
Study: NCT00934089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329
Description: Topical ocular solution, once-daily for 14 days
Study: NCT04068207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Tab. Minocycline 100mg po per day for 12 months
Study: NCT02045459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Subject will be exercising on a treadmill 3x/week. Subjects progress will dictate increases/decreases in time of exercise and pace.
Study: NCT00105573

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational meetings plus treatment as usual
Description: Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
Study: NCT03966482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group before-after
Description: The group was submitted to four weeks of speech therapy intervention with Semiocluded vocal tract exercise. The 12 participants were evaluated before and after the intervention with a multidimensional evaluation comprised of analysis of images generated by specialized videonasoendoscopy software, analysis of speech emissions by perceptual-auditory evaluation and acoustic analysis, and vocal self-assessment.
Study: NCT01615042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral capsule, daily, 50mg-100mg, one cycle (21 days)
Study: NCT04656730

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iberogast® and Iberogast® N
Description: Oral intake of the investigation drug 20 drops three times per day (TID) for 14 days,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberogast® and Iberogast® N
Description: Oral intake of the investigation drug 20 drops three times per day (TID) for 14 days,
Study: NCT02788149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Exam
Description: Ultrasound of Neck will be used to assess the Lateral parapharyngeal wall thickness. Ultrasound of neck with Submental approach will be used to assess tongue base thickness, subcutaneous fat thickness, retropalatal diameter, retroglossal diameter and upper airway length during normal tidal expiration, forced inspiration and muller's maneuver
Study: NCT02247401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 DAA
Description: ABT-450/r/ABT-267 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 DAA
Description: ABT-450/r/ABT-267 tablets
Study: NCT02788149

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Exam
Description: Ultrasound of Neck will be used to assess the Lateral parapharyngeal wall thickness. Ultrasound of neck with Submental approach will be used to assess tongue base thickness, subcutaneous fat thickness, retropalatal diameter, retroglossal diameter and upper airway length during normal tidal expiration, forced inspiration and muller's maneuver

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Full-night PSG will be performed in the sleep laboratory according to protocol of sleep medicine department after US assessment. Apnea will be defined as the absence of airflow ≥10 sec and hypopnea will be defined as \>50% decrease in airflow ≥10 sec associated with reduced arterial oxygen saturation by 4%, or an arousal. These two parameters are collectively defined as apnea-hypopnea index (AHI). An arousal will be recorded if there is a 3-second or longer abrupt shift in electroencephalogram frequency to alpha or theta or above 16 Hz, following at least 10 seconds of sleep, and, if arising in rapid eye movement sleep, there should be a rise in electromyographic tone. An independent technician blinded to the US results will analyze the sleep studies.~Episodes of AHI per hour will be used to diagnose and grade the severity of OSA:~Non-OSA : \< 5/hr mild OSA : 5- 14/hr moderate OSA :15-29/hr and severe OSA : ≥30/hr.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polysomnography
Description: Full-night PSG will be performed in the sleep laboratory according to protocol of sleep medicine department after US assessment. Apnea will be defined as the absence of airflow ≥10 sec and hypopnea will be defined as \>50% decrease in airflow ≥10 sec associated with reduced arterial oxygen saturation by 4%, or an arousal. These two parameters are collectively defined as apnea-hypopnea index (AHI). An arousal will be recorded if there is a 3-second or longer abrupt shift in electroencephalogram frequency to alpha or theta or above 16 Hz, following at least 10 seconds of sleep, and, if arising in rapid eye movement sleep, there should be a rise in electromyographic tone. An independent technician blinded to the US results will analyze the sleep studies.~Episodes of AHI per hour will be used to diagnose and grade the severity of OSA:~Non-OSA : \< 5/hr mild OSA : 5- 14/hr moderate OSA :15-29/hr and severe OSA : ≥30/hr.
Study: NCT04695756

Intervention type: OTHER
Intervention: COVID-19 pandemic
Description: The exposure of this observational study is the COVID-19 pandemic
Study: NCT02083237

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioural Intervention Program
Description: People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
Study: NCT00571285

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: 600 IU Vitamin D3 capsule daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 600 IU Vitamin D3 capsule daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 - high dose
Description: 50,000 IU Vitamin D3 capsule once a week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule given once a week
Study: NCT02290275

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Subjects will supplement their regular diet with 20 grams of creatine for 1 week and then 5 grams of creatine for the following 11 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Subjects will walk on a specialized treadmill that lowers the impact of walking by taking up to 80% of their body weight away. The subjects will exercise by walking on this treadmill at 3.1 mph, 3 days per week for 30 minutes per day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (maltodextrin)
Description: Subjects will supplement their regular diet with 20 grams of maltodextrin for 1 week and then 5 grams of maltodextrin for the following 11 weeks.
Study: NCT03531190

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (Protein + MIX)
Description: Protein supplement as needed + 750 mg vitamin C, 15 g. arginine, 35 mg. zinc and two multivitamin tablets, by mouth every day for 35 days.
Study: NCT02324010

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: 100mg mane for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive drug (Placebo)
Study: NCT02247401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 DAA
Description: ABT-450/r/ABT-267 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBV
Description: Ribavirin tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBV
Description: Ribavirin tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBV
Description: Ribavirin tablets
Study: NCT03703271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: single-agent 5-day methotrexate, two weeks a cycle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopic repeat curettage
Description: Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
Study: NCT01407393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucosanol
Description: 2 tablets 3x daily for 12 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets 3x daily for 12 weeks
Study: NCT02882815

Intervention type: DEVICE
Group type: OTHER
Intervention: IrisFIT PFO Occluder
Study: NCT03539861

Intervention type: DEVICE
Group type: OTHER
Intervention: Hemodialysis
Description: Each patient will receive two hemodialysis treatments while on this study. The first hemodialysis treatment will be standard of care hemodialysis. The second treatment will be the experimental hemodialysis treatment using the Selective cytopheretic device.
Study: NCT02790671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a
Description: DS-8500a 25mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200mg itraconazole
Study: NCT04314596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross Training Course
Description: One day of a supervised, whole body, cross-training course that is meant to produce muscle damage and soreness.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cross Training Course
Description: One day of a supervised, whole body, cross-training course that is meant to produce muscle damage and soreness.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oceanix
Description: Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
Study: NCT03571256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-50717
Description: 6-, 9-, 12-, 15-, and 18 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-50717
Description: 6-, 9-, 12-, 15-, and 18 mg oral tablets
Study: NCT03332147

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: reference group-Earlysense system
Description: The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
Study: NCT03168139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol - Monotherapy
Description: Monotherapy (MT) period:~Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks
Study: NCT03571256

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to TEV-50717 tablets will be taken BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to TEV-50717 tablets will be taken BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to TEV-50717 tablets will be taken BID.
Study: NCT02290886

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous administration of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 1 million of MSC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 2 million of MSC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 4 million of MSC
Study: NCT00808782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep rTMS
Description: Repetitive transcranial magnetic stimulation targeting the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham (non-active) repetitive transcranial magnetic stimulation over the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks
Study: NCT01006720

Intervention type: DRUG
Intervention: Sugammadex
Description: Single intravenous injection of either:~Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)

Intervention type: DRUG
Intervention: Sugammadex
Description: Single intravenous injection of either:~Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)

Intervention type: DRUG
Intervention: Sugammadex
Description: Single intravenous injection of either:~Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)

Intervention type: DRUG
Intervention: Sugammadex
Description: Single intravenous injection of either:~Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)

Intervention type: DRUG
Intervention: Sugammadex
Description: Single intravenous injection of either:~Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)
Study: NCT03168139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol + Pembrolizumab - Combination Therapy
Description: Combination therapy (CT) period:~Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total
Study: NCT00934089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost
Description: Topical ocular solution, once-daily for 14 days
Study: NCT00003473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atengenal
Description: Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astugenal
Description: Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT00049192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00002734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT01674699

Intervention type: DEVICE
Intervention: EXCOR Pediatric
Description: Ventricular Assist Device
Study: NCT05193695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Description: the patients walked on a treadmill for 20 minutes after dry needling, with an inclination of 5 degrees and at a speed at which the perceived exertion was 5 according to the Borg CR10 scale (Chen et al., 2002)
Study: NCT02270645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 595/1064 multiplex laser
Description: 595/1064 multiplex laser will be used 3 times spaced by a four week interval (+/- 3 days), it will be administered in an outpatient clinic setting.
Study: NCT02722551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve
Description: Replacement of the mitral valve through a transcatheter approach
Study: NCT02200770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Description: Participants will receive IV inebilizumab 300 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inebilizumab
Description: Participants will receive IV inebilizumab 300 mg.
Study: NCT00893360

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous stem cell infusion
Description: Subjects will receive 12.5 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous stem cell infusion
Description: Subjects will receive 25 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
Study: NCT01624714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: alemtuzumab 12 mg IV x 5 daily doses at baseline, alemtuzumab 12 mg IV x 3 daily doses at month 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: alemtuzumab 12 mg IV x 5 daily doses at baseline, alemtuzumab 12 mg IV x 3 daily doses at month 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab immunotherapy
Description: Alemtuzumab 60 mg over 5 days for first annual cycle, then 36 mg over 3 days for subsequent annual cycle, and as needed cycles in subsequent years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab immunotherapy
Description: Alemtuzumab 60 mg over 5 days for first annual cycle, then 36 mg over 3 days for subsequent annual cycle, and as needed cycles in subsequent years.
Study: NCT02199041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by intravenous infusion as part of the preparative regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given by intravenous infusion as part of the preparative regimen.
Study: NCT00002734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study: NCT02200770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive IV placebo matched to inebilizumab.